As the UK economy shows signs of recovery and investors digest recent GDP figures, the FTSE 100's positive trajectory reflects a cautiously optimistic outlook in London's financial markets. In such an environment, identifying stocks that appear undervalued relative to their intrinsic worth could offer potential opportunities for investors seeking value in a recovering market. Top 10 Undervalued Stocks Based On Cash Flows In The United Kingdom Name Current Price Fair Value (Est) Discount (Est) Kier Group (LSE:KIE) £1.45 £2.82 48.6% WPP (LSE:WPP) £7.272 £14.01 48.1% LSL Property Services (LSE:LSL) £3.29 £6.49 49.3% Auction Technology Group (LSE:ATG) £4.77 £9.22 48.2% Loungers (AIM:LGRS) £2.86 £5.55 48.5% Velocity Composites (AIM:VEL) £0.415 £0.80 48.4% Accsys Technologies (AIM:AXS) £0.55 £1.07 48.4% Ricardo (LSE:RCDO) £4.93 £9.51 48.2% Hostelworld Group (LSE:HSW) £1.53 £2.93 47.7% M&C Saatchi (AIM:SAA) £2.05 £3.98 48.5% Click here to see the full list of 63 stocks from our Undervalued UK Stocks Based On Cash Flows screener. Below we spotlight a couple of our favorites from our exclusive screener. AstraZeneca Overview: AstraZeneca PLC is a biopharmaceutical company engaged in the discovery, development, manufacture, and commercialization of prescription medicines, with a market capitalization of approximately £187.24 billion. Operations: The company's revenue from biopharmaceuticals totaled $47.61 billion. Estimated Discount To Fair Value: 39.2% AstraZeneca, a prominent player in the pharmaceutical industry, demonstrates potential underappreciation based on its cash flow metrics relative to market valuation. Recent strategic developments include a partnership with Aptamer Group plc to enhance siRNA delivery technologies, potentially boosting AstraZeneca's competitive edge in biotechnology. Moreover, regulatory advancements for its oncology products like Imfinzi and Lynparza in the EU could promise future revenue streams. However, investors should consider the inherent risks of drug development and market acceptance. These factors collectively suggest that AstraZeneca's current market pricing may not fully reflect its future cash flow generation capabilities from these innovations and approvals. Our expertly prepared growth report on AstraZeneca implies its future financial outlook may be stronger than recent results. Dive into the specifics of AstraZeneca here with our thorough financial health report. LSE:AZN Discounted Cash Flow as at Jul 2024 Gym Group Overview: The Gym Group plc operates a chain of fitness centers across the United Kingdom and has a market capitalization of approximately £237.66 million. Operations: The company generates £204 million from operating health and fitness centers. Estimated Discount To Fair Value: 34.9% Gym Group, valued at £1.33, trades below its estimated fair value of £2.04, indicating a significant undervaluation based on discounted cash flows. The company's earnings are expected to grow robustly by 91.05% annually, outpacing the UK market forecast of 3.5%. Despite challenges in achieving high Return on Equity, which is projected at a modest 1.3% in three years, Gym Group's strategic focus on ESG could enhance its growth trajectory as outlined in recent special calls and upcoming financial disclosures scheduled for July 10, 2024. The analysis detailed in our Gym Group growth report hints at robust future financial performance. Take a closer look at Gym Group's balance sheet health here in our report. LSE:GYM Discounted Cash Flow as at Jul 2024 Supermarket Income REIT Overview: Supermarket Income REIT plc (LSE: SUPR) is a UK-based real estate investment trust focusing on grocery properties, with a market capitalization of approximately £0.94 billion. Operations: The company generates revenue primarily through its real estate investment segment, totaling £106.29 million. Estimated Discount To Fair Value: 13.4% Supermarket Income REIT, priced at £0.76, is trading under its fair value of £0.87, reflecting a modest undervaluation in the UK market based on discounted cash flows. The company's earnings are anticipated to surge by 90.24% annually, significantly outperforming the UK market growth expectation of 12.5%. However, concerns exist regarding unstable dividend records and debt not being well covered by operating cash flow, which could impact financial stability. Recent affirmations of dividends align with yearly targets, supporting short-term income expectations despite underlying financial challenges. Our growth report here indicates Supermarket Income REIT may be poised for an improving outlook. Click to explore a detailed breakdown of our findings in Supermarket Income REIT's balance sheet health report. LSE:SUPR Discounted Cash Flow as at Jul 2024 Taking Advantage Embark on your investment journey to our 63 Undervalued UK Stocks Based On Cash Flows selection here. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Interested In Other Possibilities? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include LSE:AZNLSE:GYM and LSE:SUPR. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]
Three UK Exchange Stocks Estimated To Be Valued Up To 39.2% Below Intrinsic Worth
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...